- Home
- ANTA vs CGEN Comparison
ANTA vs CGEN Comparison
Compare ANTA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | CGEN |
|---|---|---|
| Founded | 2022 | 1993 |
| Country | Singapore | Israel |
| Employees | 113 | 75 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 256.2M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | ANTA | CGEN |
|---|---|---|
| Price | $8.60 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.17 | $5.00 |
| AVG Volume (30 Days) | 8.1K | ★ 555.5K |
| Earning Date | 06-16-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | $75.09 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $1.23 |
| 52 Week High | $15.65 | $3.24 |
Technical Indicators
Market Signals| Indicator | ANTA | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 51.91 |
| Support Level | $8.54 | $1.45 |
| Resistance Level | $10.12 | $3.24 |
| Average True Range (ATR) | 0.60 | 0.17 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 27.31 | 15.11 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.